

## **IN THE SPECIFICATION**

Please replace the section entitled "Figures" on pages 14-15 of the Specification as filed with the following "Brief Description of the Drawings." This section keeps parity with the drawings submitted enclosed herewith and with the amended Sequence Listing submitted on 12/20/07.

Twenty two (22) Replacement Sheets of drawings are enclosed. Their numbering is consistent with the previously submitted version.

No new matter has been added by this amendment to the specification.

### **Brief Description of the Drawings**

FIG. 1 shows UV analysis graph between 220-320 nm of the sequence I.D.# 7, sequence dFC GG ACG, lot # 120202sc1111a, and the chart below the graph shows the absorbance at 250 nm, 260 nm and 280 nm, along with the ratio of absorption between 250/260 and 260/280. The UV absorption maxima is noted at 256 nm.

FIG. 2 shows UV analysis graph between 220-320 nm of the sequence I.D.# 8, sequence dFC GTG GAA CG, lot # 120202sc1113a, and the chart below the graph shows the absorbance at 250 nm, 260 nm and 280 nm, along with the ratio of absorption at 250/260 and 260/280. The UV absorption maxima is noted at 256 nm.

FIG. 3 shows UV analysis graph between 220-320 nm of the sequence I.D.# 9, sequence dFC GGA CGT GGA ACG, lot # 120202sc1117a, and the chart below the graph shows the absorbance at 250 nm, 260 nm and 280 nm, along with the ratio of absorption at 250/260 and 260/280. The UV absorption maxima is noted at 256 nm.

FIG. 4 shows UV analysis graph between 220-320 nm of the sequence I.D.# 10, sequence dFC GGA GCT GGA ACG, lot # 120202sc1119a, and the chart below the

graph shows the absorbance at 250 nm, 260 nm and 280 nm, along with the ratio of absorption at 250/260 and 260/280. The UV absorption maxima is noted at 257 nm.

FIG. 5A shows HPLC analysis tracing of the sequence I.D.# 7, sequence dFC GG ACG, lot # 120202sc1111a with the run time of 20 minutes. The gradient profile is drawn as horizontal line going across the tracing. The gradient used has been discussed in the material and methods section.

FIG. 5B shows the chart of HPLC analysis report of the sequence I.D.# 7, sequence dFC GG ACG, lot # 120202sc1111a, with the listings of the peaks observed, their retention time in minutes, peak area, peak height, group, separation code.

FIG. 6 A shows HPLC analysis tracing of the sequence I.D.# 8 sequence dFC GTG GAA CG, lot # 120202sc1113a with the run time of 20 minutes. The gradient profile is drawn as horizontal line going across the tracing. The gradient used has been discussed in the material and methods section.

FIG. 6 B shows the chart of HPLC analysis report of the sequence I.D.#8 sequence dFC GTG GAA CG, lot # 120202sc1113a. The chart lists the peaks observed, their retention time in minutes, peak area, peak height, group, separation code.

FIG. 7 A shows HPLC analysis tracing of the sequence I.D.# 9 sequence, dFC GGA CGT GGA ACG, lot # 120202sc1117a, with the run time of 20 minutes. The gradient profile is drawn as horizontal line going across the tracing. The gradient used has been discussed in the material and methods section.

FIG. 7 B shows the chart of HPLC analysis report of the sequence I.D.#9 dFC GGA CGT GGA ACG, lot # 120202sc1117a. The chart lists the peaks observed, their retention time in minutes, peak area, peak height, group, separation code.

FIG. 8 A shows HPLC analysis tracing of the sequence I.D.# 10 sequence, dFC GGA GCT GGA ACG, lot # 120202sc1119a, with the run time of 20 minutes. The gradient profile is drawn as horizontal line going across the tracing. The gradient used has been discussed in the material and methods section.

FIG. 8 B shows the chart of HPLC analysis report of the sequence I.D.#10 dFC GGA GCT GGA ACG, lot # 120202sc1117a . The chart lists the peaks observed, their retention time in minutes, peak area, peak height, group, separation code.

FIG. 9A shows capillary gel electrophoresis ( CE) analysis tracing at 254nm of the sequence I.D.# 7, sequence dFC GG ACG, lot # 120202sc1111a. The run time of 45 minutes, sample concentration; 5.0 OD at 260 nm; injection time; 4.0 sec., injection voltage; 10 kV; separation voltage; 16 kV. The other details discussed in the material and methods section.

FIG. 9B shows the chart of CE analysis report of the sequence I.D.# 7, sequence dFC GG ACG, lot # 120202sc1111a, with the listings of the peaks observed, their migration time in minutes, area percent.

FIG. 10 A shows capillary gel electrophoresis ( CE), UV 254 nm, of the sequence I.D.# 8 sequence dFC GTG GAA CG, lot # 120202sc1113a with the run time of 45 minutes, sample concentration; 5.0 OD at 260 nm; injection time; 4.0 sec., injection voltage; 10 kV; separation voltage; 16 kV. The other details discussed in the material and methods section.

FIG. 10B shows the chart of CE analysis report of the sequence I.D.# 8, sequence dFC GTG GAA CG, lot # 120202sc1113a, with the listings of the peaks observed, their migration time in minutes, area percent.

FIG. 11 A shows capillary gel electrophoresis ( CE), UV 254 nm, of the sequence I.D.# 9 sequence dFC GGA CGT GGA ACG, lot # 120202sc1117a with the run time of 45 minutes, sample concentration; 5.0 OD at 260 nm; injection time; 4.0 sec.,

injection voltage; 10 kV; separation voltage; 16 kV. The other details discussed in the material and methods section.

FIG. 11B shows the chart of CE analysis report of the sequence I.D.# 9, sequence dFC GGA CGT GGA ACG, lot # 120202sc1117a, with the listings of the peaks observed, their migration time in minutes, area percent.

FIG. 12 A shows capillary gel electrophoresis (CE), UV 254 nm, of the sequence I.D.# 10 sequence dFC GGA GCT GGA ACG, lot # 120202sc1119a with the run time of 45 minutes, sample concentration; 5.0 OD at 260 nm; injection time; 4.0 sec., injection voltage; 10 kV; separation voltage; 16 kV. The other details discussed in the material and methods section.

FIG. 12B shows the chart of CE analysis report of the sequence I.D.# 10, sequence dFC GGA GCT GGA ACG, lot # 120202sc1119a, with the listings of the peaks observed, their migration time in minutes, area percent.

FIG. 13: Flow cytometric DNA cell cycle profiles: Effect of GEMCITABINE-ODN's on colon cancer cells, showing GEMCITABINE-ODNs, killing colon cancer cells HT29 much more effectively than by treatment with GEMCITABINE alone, at equivalent dosages. Cells were treated in culture with respective drugs for 1 hour at the stated dosage, and re incubated in normal medium without drugs for a further 47 hours. Column A is treatment by GEMCITABINE (GEMZAR) alone at 20 ng/ ml and 50 ng/ ml. column B is the treatment with GEMCITABINE-ODN- Seq. I.D.#7, column C is the treatment with GEMCITABINE-ODN- Seq. I.D.#8, column D is the treatment with GEMCITABINE-ODN- Seq. I.D.#9, column E is the treatment with GEMCITABINE-ODN- Seq. I.D.#10, at equivalent GEMCITABINE dosages, at 20 ng/ml and 50 ng/ml of each of the four sequences.

FIG. 14: Flow cytometric DNA cell cycle profiles: Effect of Gemcitabine-ODN's on colon normal cells CCD-112CO, showing Gemcitabine-ODNs killing colon normal cells CCD-112CO more effectively than by treatment with GEMCITABINE alone, at equivalent dosages. Cells were treated in culture with respective drugs for 1 hour at the stated dosage,

and reincubated in normal medium without drugs for a further 47 hours. Column A is treatment by Gemcitabine (Gemzar) alone. Column A is treatment by GEMCITABINE (GEMZAR) alone at 20 ng/ ml and 50 ng/ ml. column B is the treatment with GEMCITABINE-ODN- Seq. I.D.#7, column C is the treatment with GEMCITABINE-ODN- Seq. I.D.#8, column D is the treatment with GEMCITABINE-ODN- Seq. I.D.#9, column E is the treatment with GEMCITABINE-ODN- Seq. I.D.#10, at equivalent GEMCITABINE dosages, at 20 ng/ml and 50 ng/ml of each of the four sequences.